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As a first step in developing immuno-therapeutic vaccines for patients with chronic hepatitis B virus infection, we examined the ability of a
whole-cell vaccine, expressing the duck hepatitis B virus (DHBV) core antigen (DHBcAg), to target infected cells leading to the resolution of de
novo DHBV infections. Three separate experiments were performed. In each experiment, ducks were vaccinated at 7 and 14 days of age with
primary duck embryonic fibroblasts (PDEF) that had been transfected 48 h earlier with plasmid DNA expressing DHBcAg with and without the
addition of anti-DHBcAg (anti-DHBc) antibodies. Control ducks were injected with either 0.7% NaCl or non-transfected PDEF. The ducks were
then challenged at 18 days of age by intravenous inoculation with DHBV (5 × 108 viral genome equivalents). Liver biopsies obtained on day 4
post-challenge demonstrated that vaccination did not prevent infection of the liver as similar numbers of infected hepatocytes were detected in all
vaccinated and control ducks. However, analysis of liver tissue obtained 9 or more days post-challenge revealed that 9 out of 11 of the PDEF-
DHBcAg vaccinated ducks and 8 out of 11 ducks vaccinated with PDEF-DHBcAg plus anti-DHBc antibodies had rapidly resolved the DHBV
infection with clearance of infected cells. In contrast, 10 out of 11 of the control unvaccinated ducks developed chronic DHBV infection. In
conclusion, vaccination of ducks with a whole-cell PDEF vaccine expressing DHBcAg elicited immune responses that induced a rapid resolution
of DHBV infection. The results establish that chronic infection can be prevented via the vaccine-mediated induction of a core-antigen-specific
immune response.
© 2006 Elsevier Inc. All rights reserved.Keywords: Duck hepatitis B virus; Duck hepatitis B virus core antigen; Whole-cell vaccine; Cell-mediated immunity; Resolution of infection; Chronic virus infectionIntroduction
Infection of immuno-competent adults with the human
hepatitis B virus (HBV) results in transient infection in 90–95%
of cases. However, the remaining 5–10% of adults, as well as
90–95% of neonates, develop chronic infection (Bertoletti and
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doi:10.1016/j.virol.2005.12.032HBV infection which often leads to liver disease, cirrhosis and
hepatocellular carcinoma (Custer et al., 2004; Lavanchy, 2004).
These individuals generally have levels of HBV-specific
cytotoxic T lymphocytes (CTL) that are low or undetectable
by in vitro assays (Bertoletti and Ferrari, 2003; Bertoletti and
Naoumov, 2003; Nayersina et al., 1993; Penna et al., 1991;
Rehermann et al., 1995), though in vivo, enough reactivity is
retained to cause progressive liver damage. Current therapies
for chronic HBV infections employ nucleoside analogues or
interferon-alpha (IFN-α). However, the efficacy of these
treatments is low, with sustained responses and seroconversion
from HBV e antigen to anti-HBV e antibodies in only 10–30%
of patients (van Zonneveld et al., 2004; Wright, 2004). Thus, the
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infection remains a major goal of HBV research.
Ideally, such new treatments would activate or boost both
humoral and cell mediated immunity (CMI) to control and
eliminate the infection, as occurs during resolution of a transient
HBV infection. Indeed, chronically infected patients who
respond to nucleoside analogue and IFN-α therapy appear to
do so because their immune response to the virus is more active
than in non-responders as they have more active liver disease at
the start of therapy (van Zonneveld et al., 2004; Wright, 2004).
Better approaches are therefore needed to activate humoral and
CMI in a larger proportion of chronically HBV-infected
individuals.
A recent attempt at therapeutic vaccination for chronic HBV
infection involved a phase I clinical trial in which HBV carriers
were vaccinated with DNA vaccines expressing HBV surface
antigens (Mancini-Bourgine et al., 2004). Vaccination was
correlated with decreases in the level of HBV DNA and
transient boosting of HBV-specific interferon-gamma (IFN-γ)
producing T cells, but no vaccinated patients resolved their
HBV infection. It was therefore unclear if the DNA vaccines
induced useful CMI that might have been therapeutic if the
magnitude of the responses had been increased.
The efficacy of hepadnavirus vaccines can also be studied in
animal models, which allow determination of humoral and
CMI, as well as the outcome of viral challenge. A straightfor-
ward approach to addressing vaccine efficacy is to determine if
the vaccine protects against de novo infection and, if so, to then
commence analysis of the underlying immunological mechan-
isms. Ideally, protection with potential therapeutic value would
prime CMI against infected hepatocytes.
Early vaccine studies in hepadnavirus animal models were
directed towards generating neutralizing antibodies that pro-
tected against primary infection rather than clearance of an
established infection. Thus, vaccines containing or expressing
hepadnavirus surface antigens administered prior to viral
infection were shown to protect animals against the develop-
ment of chronic infection (Prince et al., 1997; Rollier et al.,
1999; Triyatni et al., 1998). A disadvantage of assessing surface
antigen vaccines in a virus challenge protocol is that the
humoral response to surface antigen should protect the liver
from infection, making it impossible to measure the effect of the
vaccination on induction of CMI and targeting of infected
hepatocytes.
Vaccine studies have also been performed using protein and
DNA vaccines directed to hepadnavirus core antigens, provid-
ing protection against primary infection with HBV (Murray et
al., 1987) and WHV (Lu et al., 1999; Schodel et al., 1993),
though with inconsistent efficacy. Since anti-core antibodies do
not neutralize the virus, the ability of vaccines expressing core
antigen to sometimes protect against acute infection may have
been due to priming of CMI that came into play after virus
reached the liver and successfully infected some hepatocytes,
destroying these cells before new rounds of infection occurred.
In addition, since virus particles contain both core and surface
proteins, priming of the response to core (e.g., activation of core
specific CD4+ helper cells) might also accelerate activation ofthe humoral response to surface, leading to a faster shut down of
cell-to-cell spread of virus than in unvaccinated controls.
However, in these previous studies, liver tissue was not
examined to determine if vaccination: (i) reduced the amount
of virus that reached the liver; (ii) slowed virus spread from
initially infected hepatocytes or; (iii) enhanced the rate of
elimination of infected hepatocytes. Rapid elimination of
infected cells is essential for any vaccine strategy that might
be used, not just for prevention, but also for treatment of chronic
HBV infections.
Thus, the aim of the current study was to investigate the
ability of a whole-cell vaccine comprised of primary duck
embryonic fibroblasts (PDEF) expressing duck hepatitis B
virus (DHBV) core antigen (DHBcAg) to induce an immune
response that caused rapid resolution of de novo infections
with clearance of infected hepatocytes. A whole-cell PDEF
vaccine was used in an attempt to optimize and maximize
delivery of viral core antigen to the cell type(s) most likely to
potentiate CMI via a process designated cross-priming or
cross-presentation (Heath and Carbone, 2001). It has been
shown that major histocompatibility complex (MHC) com-
patibility between the cell donor and vaccinees is not required
for this process to occur and that the cells used to present
antigen do not have to be viable (Harshyne et al., 2001;
Schulz and Reis e Sousa, 2002). The effect of adding anti-
DHBcAg antibodies (anti-DHBc) to the PDEF vaccine was
also assessed since antigen–immunoglobulin complexes are
efficiently taken up and presented to dendritic cells in vivo
(den Haan and Bevan, 2002). Four days following the second
dose of vaccine, the ducks were challenged with 5 × 108
DHBV viral genome equivalents (vge) a dose of DHBV
known from previous studies (Foster et al., 2005; Jilbert et al.,
1998) to result in the rapid spread of the virus throughout the
liver and chronic DHBV infection. Vaccine efficacy was
therefore assessed as the ability to prevent the development of
chronic DHBV infection.
We show that vaccination with the whole-cell vaccine did not
block de novo infection by DHBV, but instead primed an
immune response that rapidly cleared infected hepatocytes from
the liver, while unvaccinated control ducks developed chronic
DHBV infection. The results establish that chronic infection can
be prevented via the vaccine-mediated induction of a core-
antigen-specific immune response.
Results
Three experiments were performed to test the ability of a
whole-cell PDEF vaccine expressing DHBcAg to protect 18-
day-old ducks against the development of chronic DHBV
infection. PDEF-DHBcAg vaccines were prepared as de-
scribed in Materials and methods. In brief, PDEF were
isolated from embryonated (non-homozygous) duck eggs then
cultured in vitro for 24 h, transfected by electroporation with
plasmid DNA expressing DHBcAg and cultured in vitro for a
further 48 h to allow expression of DHBcAg. Ducks were
vaccinated by subcutaneous injection with the whole-cell
PDEF-DHBcAg vaccine with and without the addition of
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challenged at 18 days of age by intravenous inoculation with
a dose of DHBV (5 × 108 vge) known to lead to chronic
infection in ducks of this age. Control groups were injected
prior to virus challenge with either 0.7% NaCl or non-
transfected PDEF.
Control and vaccinated ducks were assessed for markers of
DHBV infection in the liver at day 4 or 9 post-challenge (p.c.)
and again at autopsy. Serum was tested throughout each
experiment for the presence of DHBV surface antigen
(DHBsAg) and for the development of anti-DHBc and anti-
DHBs antibodies. Ducks that were protected from chronic
infection did not develop detectable levels of serum DHBsAg
but did develop anti-DHBsAg antibodies. Anti-DHBc (anti-
DHBs) antibodies were detected in all vaccinated and control
ducks with a more rapid onset in the vaccinated groups. At
autopsy, carried out at 24–32 days p.c., none of the protectedFig. 1. Experiment 1. Levels of anti-DHBc antibodies (A–C), DHBsAg (D–F) and t
challenge. Ducks were injected at 7 and 14 days of age with 0.7% NaCl (A, D, G), PD
challenged with 5 × 108 DHBV vge at 18 days of age. Liver tissue was collected by bi
Titers of antibodies in each of the vaccinated and control ducks are shown and are ex
0.4 at 490 nm. The cut-off for DHBsAg, anti-DHBc and anti-DHBs-positive sample
assaying normal duck serum. = vaccination, = DHBV challenge, = autopsy.ducks had detectable levels of DHBV DNA in the liver, as
assayed by PCR, or DHBsAg-positive hepatocytes, as assayed
by immunoperoxidase staining of liver tissue sections. Each
experiment is presented in detail below.
Experiment 1
In the first experiment, prior to virus challenge, three groups
of five ducks were injected with 0.7% NaCl or with the whole-
cell PDEF vaccine expressing DHBcAg alone or in combina-
tion with duck anti-DHBc antibodies. Analysis of antibody
responses by ELISA showed that ducks vaccinated with the
whole-cell PDEF-DHBcAg rapidly developed high titers of
anti-DHBc antibodies following vaccination and virus chal-
lenge (Figs. 1B, C) compared to the 0.7% NaCl control ducks
(Fig. 1A). There were no clear differences in the anti-DHBc
antibody responses between ducks injected with the whole-cellotal anti-DHBs antibodies (G–I) in the serum following vaccination and DHBV
EF-DHBcAg (B, E, H) or PDEF-DHBcAg + anti-DHBc antibodies (C, F, I) and
opsy at 22 days of age (day 4 p.c.) and by autopsy at 47 days of age (day 29 p.c.).
pressed as the log of the reciprocal serum dilutions required to achieve an OD of
s was set at two standard deviations above the average background, obtained by
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PDEF-DHBcAg vaccine plus anti-DHBc antibodies. Following
challenge, the whole-cell PDEF-DHBcAg vaccinated ducks
also produced anti-DHBs antibodies, a marker of resolution of
infection (Figs. 1H, I), whereas most of the 0.7% NaCl-injected
controls did not (Fig. 1G).
Analysis of DHBsAg levels in the blood following DHBV
challenge provided initial evidence of the effectiveness of the
PDEF-DHBcAg vaccination regime. None of the whole-cell
PDEF-DHBcAg vaccinated ducks had detectable DHBsAg in
the serum at any time following virus challenge (Figs. 1E, F). In
contrast, all of the 0.7% NaCl-injected control ducks had
detectable serum DHBsAg during the post-challenge follow-up
(Fig. 1D). One of the vaccine control ducks (#34:35) had
transient viremia detected as serum DHBsAg at 26 days of age
(day 8 p.c.) (Fig. 1D). In this duck, the appearance of DHBsAg
coincided with production of anti-DHBs antibodies, which
persisted from 26 to 47 days of age (day 8–29 p.c.). We assume
that these antibodies form complexes with DHBsAg, thereby
removing it from the bloodstream. Duck #34:35 went on to have
a fully infected liver at autopsy as determined by immunoper-
oxidase staining of DHBsAg and PCR detection of DHBV
DNA in serum (Fig. 2A) and liver (Fig. 2B).
We have previously described the simultaneous detection
of circulating anti-DHBs antibodies and DHBsAg during
persistent DHBV infection in ducks (Foster et al., 2005).
Detection of DHBsAg under these conditions can be difficult
as the antibody masks the surface protein antigenic sites. A
similar phenomenon is observed during HBV infection whereFig. 2. Experiment 1. Levels of DHBV DNA detected by PCR in extracted
serum (A) or liver (B). Duck serum (A) or liver (B) was collected at autopsy,
extracted and then amplified by PCR using primers 2554 and 269c as described
in Materials and Methods. Twenty microliters of each PCR reaction was
electrophoresed on a 1% agarose gel stained with ethidium bromide to yield a
specific DHBV DNA band of 743 bp as shown. The limit of sensitivity was
∼500 DHBV DNA genomes. A 500 bp (M1) or 50 bp (M2) ladder was included
in the first well of each gel. DHBV DNA levels in extracted liver were also
determined by quantitative PCR using the ABI Prism 7000 and primers 390 and
666c and are shown as copies DHBV DNA per 100 ng of extracted liver cell
DNA (equivalent to 40,000 cells). The limit of sensitivity was 10 copies of
DHBV DNA. ND = not detected. NEG = DNA extracted from the serum and
liver of two DHBV-negative control ducks.immune complexes formed between circulating HBsAg and
anti-HBs antibodies are readily detected in humans with acute
and persistent HBV infection (Surelia and Boxall, 1990; Tsai
et al., 1995, 1998).
In concordance with the DHBsAg data, PCR analysis of
autopsy samples failed to detect DHBV DNA in the serum of
PDEF-DHBcAg vaccinated ducks, while the serum of all 0.7%
NaCl-injected control ducks was DHBV DNA-positive at week
9 p.c. (Fig. 2A).
Immunoperoxidase staining of liver tissue collected at biopsy
on day 4 p.c. revealed similar percentages of DHBsAg-positive
hepatocytes in both the PDEF-DHBcAg vaccinated ducks (1.4–
3.0%DHBsAg-positive) and 0.7%NaCl-injected controls (0.6–
2.7% DHBsAg-positive; Table 1). The level of infiltrating
inflammatory cells was moderately increased in the animals that
had received the PDEF-DHBcAg vaccines. This inflammation
had disappeared by the end of the study at 29 days p.c. At
autopsy, none of the PDEF-DHBcAg vaccinated ducks had any
detectable DHBsAg-positive cells in the liver, while N95% of
hepatocytes were DHBV-infected and stained positive for
DHBsAg in the 0.7% NaCl injected control ducks (Table 1).
To confirm that the liver of the PDEF-DHBcAg vaccinated
ducks was DHBV DNA-negative, total DNA samples were
extracted from autopsy liver and subjected to PCR analysis for
DHBV DNA. Again, all PDEF-DHBcAg-vaccinated ducks
(with and without the addition of anti-DHBc antibodies) had
undetectable levels of DHBV DNA (less than 10 copies per 100
ng of extracted liver cell DNA), while the liver of all 5, 0.7%
NaCl-injected control ducks, had 6.0 × 105–1.7 × 107 DHBV
DNA genomes per 100 ng (Fig. 2B).
Experiment 2
The next experiment was performed to determine if
protection was due to expression of DHBcAg by the transfected
PDEF, or to the antigenicity of the PDEF, as they were not
derived from histocompatible or inbred ducks. Three groups of
three ducks were vaccinated with non-transfected PDEF or
PDEF-DHBcAg with or without the addition of duck anti-
DHBc antibodies. All ducks were biopsied on day 4 p.c. and
autopsied on day 32 p.c. Again, the humoral immune response
in the PDEF-DHBcAg vaccinated ducks was rapid, with many
of the ducks producing anti-DHBc antibodies shortly after the
first dose of vaccine (Figs. 3B, C). Following DHBV challenge,
the ducks vaccinated with the whole-cell PDEF-DHBcAg (Figs.
3B, C) developed high titers of anti-DHBc antibodies more
rapidly than the PDEF control ducks where anti-DHBc
antibodies were first detected at 28 days of age, on day 14
p.c. (Fig. 3A). Levels of anti-DHBs antibodies fluctuated
throughout this experiment in most PDEF-DHBcAg vaccinat-
ed animals (Figs. 3H, I). Two of the PDEF vaccine control
ducks (#54 and #56; Fig. 3G) also developed detectable anti-
DHBs antibodies.
From the biopsy at day 4 p.c., it was clear that all ducks had
been successfully infected with DHBV as liver tissue from all
PDEF-DHBcAg vaccinated and PDEF control ducks had
between 1.0 and 3.3% of DHBsAg-positive hepatocytes.
Table 1
Vaccine Duck # % DHBsAg + ve
hepatocytes
Day 4 p.c. a, b
% DHBsAg + ve
hepatocytes
Day 9 p.c. a, b
% DHBsAg + ve
hepatocytes
autopsy a, b
Experiment 1 0.7% NaCl control 30:31 1.4 nt N95
32:33 0.6 nt N95
34:35 2.7 nt N95
36:37 1.2 nt N95
38:39 1.1 nt N95
PDEF-DHBcAg 40:41 1.6 nt b0.0001 b
42:43 1.6 nt b0.0001
44:45 1.7 nt b0.0001
46:47 1.7 nt b0.0001
48:49 1.4 nt b0.0001
PDEF-DHBcAg + Anti-DHBc 76 1.6 nt b0.0001
78 1.8 nt b0.0001
80 3.0 nt b0.0001
82 1.4 nt b0.0001
84 2.0 nt b0.0001
Experiment 2 PDEF control 54 2.5 nt N95
55 2.8 nt N95
56 b0.001 b nt b0.0001
PDEF-DHBcAg 57 3.1 nt b0.0001
58 1.5 nt b0.0001
59 3.3 nt b0.0001
PDEF-DHBcAg + Anti-DHBc 60 3.0 nt b0.0001
61 1.8 nt N95
62 1.7 nt N95
Experiment 3 PDEF control 89:90 nt N95 N95
91:92 nt N95 N95
93:94 nt N95 N95
PDEF-DHBcAg 76:77 nt b0.001 b0.0001
78:79 nt N95 N95
80:81 nt N95 N95
PDEF-DHBcAg + Anti-DHBc 82:84 nt b0.001 b0.0001
85:86 nt N95 N95
87:88 nt b0.001 b0.0001
a Liver biopsy tissue was collected in Experiments 1 and 2 at day 4 and in Experiment 3 at day 9 p.c. Autopsy tissue was collected in Experiments 1, 2 and 3 at day
29, 32 and 24 p.c.
b The percentage of DHBsAg-positive hepatocytes was determined by immunoperoxidase staining of ethanol acetic acid fixed liver tissue with anti-preS monoclonal
antibodies and counting with an eyepiece graticule as described in the text. The minimum sensitivity of detection of DHBsAg-positive hepatocytes was 0.001% for
biopsy and 0.0001% for autopsy liver tissue.
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alone had b0.001% of hepatocytes DHBsAg-positive at day
4 p.c. and at autopsy at day 32 p.c. (Table 1). This duck was also
serum DHBsAg-negative (Fig. 3D) but had developed serum
anti-DHBc (Fig. 3A) and anti-DHBs antibodies (Fig. 3G),
indicating that this duck had been infected but had cleared its
DHBV infection.
The levels of serum DHBsAg revealed that 3 out of 3 ducks
vaccinated with PDEF-DHBcAg (#57, #58 and #59) and 1 out
of 3 ducks vaccinated with PDEF-DHBcAg with added anti-
DHBc antibodies (#60) had no detectable DHBsAg present
during the study (Figs. 3E, F) and were protected from the
development of chronic DHBV infection. Testing of liver at
autopsy also showed an absence of DHBV-infected DHBsAg-
positive hepatocytes (Table 1). However, 2 ducks that received
the PDEF-DHBcAg vaccine in combination with duck anti-
DHBc antibodies (#61, #62) that had DHBV-infected cells
present on day 4 p.c. were not protected from the developmentof chronic DHBV infection, and, by day 32 p.c., infection had
spread throughout the liver to infect N95% of hepatocytes. The
failure of vaccination to prevent the development of chronic
DHBV infection demonstrates that the protection afforded by
the PDEF-DHBcAg vaccine is not 100% effective. Although
duck #62 developed anti-DHBc antibodies slightly later than
the other 2 vaccinated ducks in this group (Fig. 3C), anti-DHBc
antibodies were still detected earlier than in the PDEF control
ducks (Fig. 3A), suggesting that vaccination had induced
humoral immunity but the CMI was not sufficient to prevent the
development of chronic DHBV infection.
Experiment 3
A third experiment was performed with 2 significant
changes, firstly in order to determine if the number of cells in
the vaccine had an effect, the number of PDEF in each dose was
reduced to ∼1/3 of that used in the first 2 experiments (that is, a
Fig. 3. Experiment 2. Levels of anti-DHBc antibodies (A–C), DHBsAg (D–F) and total anti-DHBs antibodies (H–I) in the serum following vaccination and DHBV
challenge. Three groups of three ducks were injected at 7 and 14 days of age with either PDEF (A, D, G), PDEF-DHBcAg (B, E, H) or PDEF-DHBcAg + anti-DHBc
antibodies (C, F, I) and challengedwith 5 × 108 DHBVvge at 18 days of age. Liver tissue was collected by biopsy at 22 days of age (day 4 p.c.) and by autopsy at 50 days
of age (day 32 p.c.). Titers of antibodies and DHBsAg were determined as described in the legend to Fig. 1. = vaccination, = DHBV challenge, = autopsy.
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Experiments 1 and 2). Secondly, biopsy liver samples were
collected at day 9 p.c. to determine if infected cells, detected on
day 4 p.c. in Experiments 1 and 2, had been cleared from the
liver by day 9 p.c., giving us an indication of the timing of the
immune response and cleared of the DHBV-infected hepato-
cytes in Experiments 1 and 2.
Three groups of three ducks were vaccinated with non-
transfected PDEF, or with PDEF-DHBcAg with or without the
addition of duck anti-DHBc antibodies. Analysis of serum
revealed that no PDEF-DHBcAg vaccinated ducks developed
detectable anti-DHBc antibodies prior to challenge. However,
following challenge, the levels of anti-DHBc antibodiesdeveloped more rapidly in the ducks that received the PDEF-
DHBcAg vaccines (Figs. 4B, C) compared to the PDEF controls
(Fig. 4A), suggesting that vaccination had primed the
production of anti-DHBc antibodies that were boosted follow-
ing virus challenge. One of the PDEF control ducks (#93:94)
did not generate detectable anti-DHBc antibodies even after
virus challenge (Fig. 4A), although this animal became
chronically DHBV-infected (Table 1). Analyses of the raw
data show that duck #93:94 had low levels of anti-DHBc
antibodies, but these were below the cut-off for the assay which
is set at two standard deviations above the average background,
obtained by assaying normal duck serum. The low levels of
anti-DHBc antibodies in duck #93:94 could also be explained in
Fig. 4. Experiment 3. Levels of anti-DHBc antibodies (A–C), DHBsAg (D–F) and total anti-DHBs antibodies (G–I) in the serum following vaccination and DHBV
challenge. Three groups of three ducks were injected at 7 and 14 of age with either PDEF (A, D, G), PDEF-DHBcAg (B, E, H) or PDEF-DHBcAg + anti-DHBc
antibodies (C, F, I). Liver tissue was collected by biopsy at 27 days of age (day 9 p.c.) and by autopsy at 42 days of age (day 24 p.c.). Titers of antibodies and DHBsAg
were determined as described in the legend to Fig. 1. = vaccination, = DHBV challenge, = autopsy.
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to respond differently to the virus.
In this experiment, vaccination with the whole-cell PDEF-
DHBcAg vaccine again resulted in protection against the
development of chronic DHBV infection in 1 out of 3 ducks
(#76:77) that received the vaccine alone and 2 out of 3 that
received the vaccine plus anti-DHBc antibodies (#82:84,
#87:88). In general, the protection afforded in this Experiment
was lower than Experiments 1 and 2. This may have resultedfrom the lower dose of vaccine as each dose of PDEF-DHBcAg
was reduced to ∼1/3 of that used in Experiments 1 and 2.
Protection against chronic infection was demonstrated by an
absence of DHBsAg in the serum (Figs. 4E, F). In concordance
with the serum DHBsAg data, these protected ducks had no
detectable DHBsAg-positive hepatocytes present in the liver on
day 9 p.c. or at autopsy on day 24 p.c. (Table 1). In contrast, all
three of the PDEF control ducks and the 3 other whole-cell
PDEF-DHBcAg vaccinated ducks were not protected and had
304 D.S. Miller et al. / Virology 348 (2006) 297–308N95% of hepatocytes staining DHBsAg-positive at day 24 p.c.
(Table 1).
Anti-DHBs antibodies were detected sooner in the ducks that
received the PDEF-DHBcAg vaccine with highest levels in the
ducks that were protected from chronic infection (Figs. 4H, I).
In some cases, anti-DHBs antibodies were present in samples
that also contained DHBsAg, presumably circulating as
immune complexes (Foster et al., 2005; Surelia and Boxall,
1990; Tsai et al., 1995, 1998) as also described for HBV.
Statistical analysis of the outcome of infection
Although the numbers of ducks in each vaccine group were
small, statistical analysis of the combined data from all 3
experiments was performed using log-binomial regression.
Resolution of DHBV infection occurred in 9 of 11 ducks
vaccinated with PDEF-DHBcAg compared to 1 of 11 control
ducks (P b 0.05). Similarly, resolution of infection also occurred
in 8 of 11 PDEF-DHBcAg vaccinated ducks that also received
anti-DHBc antibodies, compared to 1 of 11 control ducks
(P b 0.05). No statistical difference was observed between the 2
PDEF-DHBcAg vaccine groups with and without the addition
of anti-DHBc antibodies (P b 0.81; Table 2).
Discussion
Effective IFN-α therapy for chronic HBV infection appears
to induce an acute hepatitis that eliminates the infection in a
similar way that the host is thought to clear a transient HBV
infection, that is, through the production of inflammatory
cytokines to block virus replication, antigen-specific CTL to kill
infected hepatocytes and neutralizing antibodies to prevent
reinfection of cells and virus rebound (Bertoletti and Ferrari,
2003). Thus, the immediate goal in the development of
therapeutic vaccines for chronic HBV infection is to induce
one or more of these steps in virus clearance. We report here on
the development of a protective vaccine that appears to induce
immune responses that eliminate DHBV-infected hepatocytes.
Our vaccine approach involved the use of whole cells
(PDEF) expressing DHBcAg. As the PDEF vaccine was
derived from non-homologous duck embryos the vast majority
of the vaccinated ducks would have received allogeneicTable 2
Summary and statistical analysis of the effect of whole cell vaccination on the outco
a The resolution of DHBV infection was defined at autopsy as the absence of DHBs
DNA and development of anti-DHBs antibodies.
b Statistical analysis was performed using log-binomial regression as described in
comparing the PDEF-DHBcAg and control groups (P b 0.05) and the PDEF-DHBc
c No statistical difference in the outcome ofDHBVinfectionwas observed between t
antibodies;Pb 0.81).fibroblasts. This same strategy could be used for vaccination
of humans with allogeneic cells, thereby allowing non-
customized vaccination with, for example, a common human
fibroblast line. T-cell priming in the context of allogeneic
vaccination is believed to occur via an in vivo cross priming or
cross-presentation mechanism in which an early obligatory step
is the capture by host dendritic cells of the antigen expressed by
the vaccine cells. This mechanism would not be restricted to
allogeneic transfer of the fibroblasts but would also operate in
MHC-matched transfer during vaccination. This latter consid-
eration means that customized vaccination using the patient's
own fibroblasts would also be a viable vaccine strategy
although one that is a priori clearly less attractive, simply on
a cost basis, than the use of allogeneic vaccination.
The current study used the DHBV model, in which the dose-
and age-related outcomes of infection have been clearly
defined. Our results showed that vaccination with PDEF-
DHBcAg does not prevent, or reduce, the number of
hepatocytes that are initially infected with DHBV. However,
while unvaccinated control ducks rapidly developed chronic
DHBV infection with widespread infection of hepatocytes,
vaccinated ducks rapidly cleared their infected cells and
resolved the infection (Table 1). Analysis of the combined
data from all 3 experiments (Table 2) demonstrated that the
differences in outcome of DHBV infection between vaccinated
and control groups were statistically significant. Although the
duration of protection was not tested later than 4 days after
vaccination, it is likely that T cell responses persist and may still
be increasing at the time of virus challenge.
The ability of hepadnavirus core antigens to protect against
HBVand WHV infections has been assessed in previous studies
in chimpanzees (Murray et al., 1987) and woodchucks (Schodel
et al., 1993). In the study by Murray et al. (1987), two
chimpanzees were vaccinated using SDS-treated and denatured
HBV core particles combined with alum adjuvant. In the second
study, recombinant WHV core antigen expressed in E. coli was
combined with Freund's adjuvant and used to vaccinate 6
woodchucks (Schodel et al., 1993). In both of these studies,
levels of viremia were reduced following challenge, but liver
tissue was not examined for viral replication early after virus
inoculation. It was therefore unclear in these previous studies if
vaccination reduced the percentage of initially infected cells,me of DHBV injection
Ag-positive hepatocytes in the liver, the absence of serum DHBsAg and DHBV
the text. Statistical differences in the outcome of DHBV infection were found
Ag + anti-DHBc and control groups (P b 0.05).
he 2 PDEF-DHBcAg vaccine groups (with andwithout the addition of anti-DHBc
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anti-surface response. In both the HBV and WHV models,
challenge of unvaccinated adult animals results in transient
infection, making it difficult to assess the effects of vaccination
on outcome. In contrast in the current study performed in 18-
day-old ducks, 10 out of 11 control unvaccinated animals
developed chronic DHBV infection.
In other studies, DNA vaccines expressing WHV core
antigen have been used to vaccinate woodchucks prior to
challenge with WHV. The reproducibility of the vaccine
response was not clear, and, because the studies were performed
in adult woodchucks, prevention of chronic WHV infection was
not used to assess the efficacy of vaccination. In an initial DNA
vaccine trial (Lu et al., 1999), complete protection against WHV
challenge was reported, based on measurements of viremia,
whereas in a second DNAvaccine trial (Siegel et al., 2001) with
the same challenge dose of WHV, vaccination did not protect. In
fact, similar levels of viremia were observed in the WHV core
vaccinated and control animals. Even in the unvaccinated
control animals, the duration of viremia appeared short lived,
and the appearance of anti-surface antibodies was rapid,
compared to our own and other published data with the WHV
model. This suggested that the inoculum itself might have
induced an anti-surface response that shut down viremia and
spread of virus, as apparently also happened in a study of
transient WHV infection (Guo et al., 2000). Finally, no liver
biopsies were taken, so it is unclear how much if at all spread of
infection was limited prior to the early appearance of anti-
surface antibodies. In brief, these initial studies appeared
promising, but a need for a more detailed analysis examining
the effects of vaccination on virus spread through the liver was
clearly needed.
Our approach could in theory provide both the stimulus
obtained with the DNA vaccination protocol in addition to the
vaccine effect of the whole-cell preparation. That is, in addition
to the likelihood that dendritic cells cross-presented cell-
associated antigen, it is possible that some of the cell-associated
plasmid DNA encoding DHBcAg was phagocytosed and
ultimately expressed within these cells. Finally, an important
consideration that justifies a focus on cell-based vaccines is the
present general low efficacy of naked DNAvaccines in humans,
despite the success achieved in other mammalian systems.
Because it has been previously shown that antibodies bound
to antigen facilitate Fc-receptor-specific uptake of the antigen
(Amigorena, 2002), they can be considered as antigen receptors
for phagocytes/dendritic cells. Theoretically, in the presence of
antibodies to DHBcAg, core antigen released from dead or
dying PDEF could form antigen/antibody complexes with
enhanced uptake and cross-presentation to both the humoral and
cell-mediated arms of the immune system, i.e., in both a class I
and class II context. However, in our experiments, we found
little evidence for an effect of anti-DHBc antibodies on the
efficacy of vaccination.
With regard to the protection afforded by our vaccine, we
know that it cannot be explained by opsonization of input virus
by vaccine-induced anti-DHBc antibodies. Aside from the fact
that core antigen has never been reported on the virus surface,this can be inferred from the results of immunoperoxidase
staining of the day 4 p.c. biopsy tissues in Experiments 1 and 2.
There was no significant difference in the number of
hepatocytes that stained positive for DHBsAg at day 4 p.c. in
the PDEF-DHBcAg vaccinated and control ducks. In addition,
more direct assays have shown that anti-core antibodies are
unable to opsonize either DHBV or HBV (D.S. Miller, in
preparation) (Panda et al., 1988). The data instead are consistent
with the possibility that CMI directed against DHBcAg is
responsible for control of the infection. Given the difficulty in
assaying for CMI activity of outbred avian species, this issue
may be better addressed in a mammalian model of hepadnavirus
infection. If CMI involvement proves key optimizing vaccine,
protocols to induce CMI activity may offer the possibility of
post-exposure treatments and therapy for those individuals who
are chronically HBV-infected, especially in conjunction with
nucleoside analogue treatment to reduce viral replication and
antigen load.
Our studies demonstrate that hepadnavival core antigen
elicits protective immune responses that are able to stimulate
clearance of virus-infected cells. The current HBV vaccine is
composed of HBsAg. It is likely that addition of HBcAg to the
vaccine may, firstly, provide additional coverage to immunized
individuals and, secondly, may elicit immune responses in those
individuals who do not respond to the current HBsAg vaccine.
To develop an immuno-therapeutic vaccine is not an easy task
and it is likely that it would need to contain several different
vaccine antigens. Therefore, it is a requirement to validate the
effectiveness of each individual antigen, albeit, in this case, in a
protective setting. Based on the results presented in this study,
we are investigating the effectiveness of combination antiviral
and vaccine therapies to treat chronic DHBV infection.
Materials and methods
Animals
DHBV-negative, 1-day-old Pekin Aylesbury ducks (Anas
platyrhynchos domesticus) and day-12 embryonated duck eggs
were purchased from a commercial duck hatchery. Congenitally
DHBV-infected ducks were purchased from a second commer-
cial duck hatchery. Both hatcheries breed the animals as closed
colonies. All animal handling protocols were assessed,
approved and carried out in accordance with the guidelines of
the University of Adelaide and Institute of Medical and
Veterinary Science animal ethics committees and the National
Health and Medical Research Council (NHMRC) of Australia.
Isolation and in vitro culture of PDEF
PDEF were isolated from DHBV-negative day-12 embryo-
nated (non-homozygous) duck eggs, essentially as described
(Vogt, 1969). Embryos were decapitated and eviscerated,
loosely dissociated by mechanical disruption and then digested
with 0.1% (w/v) trypsin (Gibco–BRL # 27250-18) in PBS for
30 min at 37 °C. The cells were then suspended in PDEF
medium (RPMI 1640 containing 5% normal duck serum, 12 μg/
306 D.S. Miller et al. / Virology 348 (2006) 297–308ml penicillin and 16 μg/ml gentamycin), dispensed into 150
cm2 tissue culture flasks and allowed to attach and grow
overnight in a 5% CO2 incubator at 37 °C.
Transfection of PDEF with plasmid DNA expressing DHBcAg
and addition of anti-DHBc antibodies
Plasmid DNA expressing DHBcAg, pTC-Dcore (von
Weizsacker et al., 1995), was kindly provided by Dr. Fritz
vonWeizsacker from the Department of Medicine II, University
Hospital, Freiburg, Germany. The plasmid DNA was grown in
E. coli purified using the Plasmid Maxi kit (Qiagen #12162) and
redissolved in distilled water at a concentration of 1 mg/ml.
Following culture for 24 h, the monolayers of PDEF were
washed, trypsinized and resuspended in Hanks Balanced Salt
Solution at a concentration of 1 × 107 cells/ml. 500 μl of the
PDEF suspension and 50 μg of the plasmid DNA expressing
DHBcAg were then placed into a 0.4 cm electroporation cuvette
(Gene Pulser, Bio-Rad), chilled for 10 min and electroporated
using a Bio-Rad Gene Pulser with capacitance extender at a
capacitance of 960 μFD and a voltage 0.35 of kV. The time
constant under these conditions was 31 ms. Following
electroporation, the contents of three cuvettes (1.5 × 107 cells)
were pooled and cultured for a further 48 h in PDEF medium in
a 10 cm diameter petri dish to allow antigen expression from the
transfected DNA. The electroporation efficiency was assessed
for each batch of cells by direct immunofluorescence using
rabbit anti-DHBc antibodies as described below. The transfec-
tion efficiency was 20–40%. Under these electroporation
conditions, approximately 50% of the PDEF were killed. This
resulted in the formation of large clumps of transfected PDEF.
For this reason, the wet weight of the transfected PDEF was
determined by weighing on a microbalance rather than by
counting individual cells.
On the day of vaccination (48 h after transfection), the
transfected PDEF or non-transfected control PDEF were
harvested from ten petri dishes by vigorous pipetting and
scraping with a rubber policeman. Cells were washed in PBS,
pelleted and the wet weight of the cells was measured. The
PDEF were then resuspended in 3 ml of 0.7% NaCl. Where
duck anti-DHBc antibodies were included, 200 μl of duck anti-
DHBc antibodies (prepared as described below) was added to
the transfected PDEF, and the mixture was incubated at 37 °C
for 45 min. 0.7% NaCl was then added to increase the volume to
ensure that each duck received 1 ml of the PDEF and antibody
mixture. Animals were injected subcutaneously with 5 × 107
transfected or non-transfected control PDEF in 1 ml of 0.7%
0.7% NaCl or PBS.
Preparation of duck anti-DHBc antibodies
Recombinant DHBV core protein (rDHBcAg) was prepared
as previously described (Jilbert et al., 1992) with some
modifications to the procedure. Briefly, freeze/thaw lysates of
E. coli expressing rDHBcAg were loaded onto a 10–30% linear
sucrose gradient and centrifuged at 33,000 rpm for 3 h.
Fractions were collected from the bottom of the gradient andsubjected to PAGE analysis to assess the quantity and purity of
the rDHBcAg. Three 50 μg doses of purified rDHBcAg in
Freund's incomplete adjuvant were administered by subcuta-
neous injection to three sites across the back of an adult duck at
2-week intervals. The levels of duck anti-DHBc antibodies were
determined by ELISA, and serum was collected on days 7 and
14 following the final injection.
Detection of DHBcAg expression in transfected PDEF
PDEF transfected with plasmid DNA expressing DHBcAg,
prepared as described above, were cultured in 24-well trays and
assayed to determine the efficiency of transfection. Expression
of DHBcAg was detected 48 h after transfection by fixation of
the PDEF with 95% methanol for 10 min. The methanol was
then removed, and the cells were washed two times with PBS
then blocked with PBS + 10% fetal calf serum (FCS) for 1 h at
37 °C followed by immunofluorescence with rabbit anti-rDHBc
antibodies (Jilbert et al., 1992) and goat anti-rabbit FITC
(Kirkegaard and Perry Laboratories, Inc., Gaithsburg, MD).
Preparation of DHBV stocks and inoculum
The DHBV used for inoculation was derived from a pool
(Pool 7) of serum from 34-day-old ducks congenitally infected
with the Australian strain of DHBV (Triyatni et al., 2001). The
serum was filtered through a 0.2 μM filter, aliquoted and stored
at −80 °C. The serum pool contained 5 × 109 DHBV vge/ml and
50 μg/ml of DHBsAg. Previous studies have shown it to be
highly infectious in neonatal ducks (Jilbert et al., 1996). Ducks
were inoculated intravenously at 18 days of age with 100 μl of
pooled serum containing DHBV (5 × 108 vge).
Vaccination and DHBV challenge protocol
Three experiments were performed using DHBV-negative
ducks injected with 1 ml of PDEF vaccine, either with or
without the addition of duck anti-DHBc antibodies, by the
subcutaneous route on days 7 and 14 of age. In Experiment 1,
ducks were vaccinated with 5 × 107 PDEF-DHBcAg. A control
group was injected with 0.7% NaCl only. In Experiment 2,
ducks were vaccinated with 5 × 107 PDEF-DHBcAg, while the
control group received 5 × 107 non-transfected PDEF. In
Experiment 3, ducks were vaccinated with 1.5 × 107 PDEF-
DHBcAg, while the control group received 1.5 × 107 non-
transfected PDEF. All ducks were then challenged intravenous-
ly with DHBV (5 × 108 vge) at 18 days of age. Liver biopsies
were collected on day 4 (Experiments 1 and 2) or day 9
(Experiment 3) p.c., and autopsy tissue was collected on day 29,
32 and day 24 p.c. in Experiments 1, 2 and 3 respectively.
Analysis of serum and liver tissue
Serum samples were collected weekly and assayed for levels
of total anti-DHBs, anti-DHBc antibodies and DHBsAg by
ELISA as previously described (Foster et al., 2003; Jilbert et al.,
1996; Miller et al., 2004; Pugh et al., 1995). To assess the extent
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from each duck on day 4 p.c. (Experiments 1 and 2) or day 9 p.c.
(Experiment 3). Liver, spleen, pancreas and kidney tissue were
also taken from all ducks at autopsy during week 4 p.c. (day 24–
32 p.i.). Biopsy samples of liver and autopsy samples of liver,
kidney, pancreas and spleen were fixed in ethanol:acetic acid,
wax-embedded, sectioned and examined for DHBsAg by
immunoperoxidase staining as a marker of infected cells (Foster
et al., 2003, 2005; Miller et al., 2004; Triyatni et al., 1998). The
nuclei of hepatocytes staining positive for DHBsAg were
counted in liver biopsy tissue with the aid of an eyepiece
graticule in 200, 250 × 250 mm grid fields and expressed as a
percentage of the average total hepatocyte nuclei. The minimum
sensitivity of detection in liver biopsy tissue was 0.001%. In
autopsy liver samples 2000, 250 × 250 mm grid fields were
counted for each duck resulting in minimum sensitivity of
detection of 0.0001% (Foster et al., 2005; Meier et al., 2003; Le
Mire et al., 2005).
Extraction and PCR amplification of liver and serum DNA
A volume of 200 μl of each serum sample was treated with
protease and extracted using a High Pure Viral Nucleic Acid kit
(Roche 1 858 874). The final volume eluted from the column
was 50 μl. To isolate total liver DNA, 25 mg of each liver
sample was extracted using a DNeasy Tissue kit (Qiagen
69504). The volume eluted from the column was 100 μl. The
efficiency of the extraction procedure was determined by
measuring the optical density of each sample at 260 nm. DNA
content ranged from 8 to 34 μg/ml. Samples were stored at −20
°C until required. PCR primers were designed to amplify part of
the DHBV DHBcAg gene. The primers were located at nt 2554
(5′-TTCGGAGCTGCCTGCCAAGG-3′) for the forward prim-
er and nt 269c (5′-CTAGGTTCGAGTCCACGAGG-3′) for the
primer that amplified the complementary strand (Triyatni et al.,
2001). The predicted size of this PCR product was 743 bp. A
standard 50 μl PCR reaction mix was used containing 20 μM of
each primer, 1× reaction buffer, 200 μM dNTPs, 1.64 mM
MgCl2 and 1 U of Taq polymerase for each reaction. The
template for each PCR reaction was 5 μl containing DNA
extracted from 6.25 mg of liver or 5 μl of DNA extracted from
20 μl of serum. The limit of detection for DHBV DNA in the
serum and extracted liver tissue was ∼500 genomes.
DHBV DNA levels in autopsy liver tissues collected in
Experiment 1 were also determined by quantitative PCR using
the ABI Prism 7000. A head-to-tail dimer of DHBV inserted
into pBluescript II KS (+) (p4.8BLx2) (Triyatni et al., 2001) was
used to generate a standard curve of 108–101 copies of the
dimer in 10 μl supplemented with 100 ng of DNA extracted
from normal duck liver. The volume of each PCR reaction was
25 μl and consisted of 100 ng of extracted DNA (2.5 μl adjusted
to 10 μl with water), 12.5 μl of QuantiTect Sybr Green Master
Mix, 50 nM of primer nt 390 (nucleotide sequence 5′-
CAGATCTCCCTCGCCTAGGA-3′) and 300 nM of the primer
nt 666c (nucleotide sequence 5′-ATTGCCTCATGCTGCAT-
CAC-3′). The cycling parameters for the reaction were an
initial 95 °C for 10 min then 40 cycles of 95 °C for 15 s and60 °C for 1 min. The limit of sensitivity was 10 copies of
DHBV DNA per 100 ng of extracted liver cell DNA
(equivalent to 40,000 cells).
Statistical analysis
The binary outcome (resolution of infection) was analyzed
using log-binomial regression with adjustment for each
experiment. The normally distributed outcome of the number
of hepatocytes positive was analyzed using a mixed model
ANOVA to allow for repeated measures over time with
adjustment for each experiment. Post hoc testing was used to
look at pair-wise comparisons between the treatments with no
adjustment made for multiple comparisons. Significance was
assessed at the 5% level. All analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC, USA).
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